Lighting the Way to

Better Brain Health

Boost Your Gamma Brainwaves to Achieve Peak Performance

6
Enhanced Brain Health Technology

Improve Mental Acuity & Cognitive Performance

1
Backed by Science

Safe and Effective Technology

Currently in Clinical Trial

2
Home-based Care

Easy Implementable into your Daily Routines

brain health

Brain Disorders Affect Over One Billion People Worldwide

Mental and neurological disorders ranging from migraines to depression and dementia affect over 1 billion people worldwide and the toll will rise as the population ages. Due to strong stigma, lack of treatment options, and medication side effects, most people are left suffering.

It’s time to transform brain health — advancing health solutions to support everyone on the planet in achieving higher quality of life.

OPTOCEUTICS
Risorsa 2 8

sentiment satisfied alt white 24dp    EASY TO USE

favorite border white 24dp    COMFORTABLE

cancel white 24dp    NON-INVASIVE

In collaboration with:

The University of California Berkeley 1868 ws 1dtu 1 logo black and white

Non-invasive 40 Hz Neurostimulation as a Tool for Better Brain Health

It has been demonstrated that light flickering at 40 Hz effectively entrains gamma waves in the human brain. These waves are correlated with large brain network activity and have an impact on cognition, memory and mood.

Our novel technology, EVY LIGHT, is designed to maximize comfort and efficacy by eliminating the perceived flicker from 40 Hz light whilst retaining the intended stimulus in the brain.

homepage collage 1024x1024 1

Investigating Gamma Brain Waves for Alzheimer’s Disease

OptoCeutics is currently conducting clinical studies to investigate the potential therapeutical effects of masked 40 Hz flickering light on Alzheimer’s disease patients.

DISCLAIMER: All devices used in trials are considered investigational devices and limited to investigational use only.

Selected Partners

Press & Mentions

Read more about the team behind the project.

Where to Find Us

Newsletter

Sign-up to our newsletter and receive new information about our developments, clinical trials and more.